Personalizing and improving the earlier detection of aggressive prostate cancer.

1 in 9 men will develop prostate cancer in their lifetime.  What is your risk for aggressive, potentially lethal, prostate cancer? 

A non-invasive urine test to improve patient selection for initial biopsy.

Included in the 2020 National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection.

 

A tissue test that improves patient stratification for repeat biopsy so you can focus on finding aggressive prostate cancer.

The non-invasive ConfirmMDx test established MDxHealth® as a market leader in the critical and growing field of cancer epigenetics. With SelectMDx, we’re using the powerful cancer-detection properties of these genetic markers to improve and personalize prostate cancer testing and treatment further.

Physicians

Providing physicians with innovative and meaningful assays for the earlier detection of clinically significantly prostate cancer.

Patients

Learn about the ability of our genomic tests to improve and personalize the diagnosis and treatment of cancer.

Science &
Technology

Leveraging our methylation specific PCR technology (MSP) and portfolio of genes, for diagnostic, prognostic, and predictive molecular assays.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer.

News & Events

Stay up to date on the MDxHealth news, including clinical validation studies, company news, and the conferences and seminars around the globe that we’ll present at throughout the year.